Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll (Q80199403)
Jump to navigation
Jump to search
scientific article published on 31 August 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll |
scientific article published on 31 August 2006 |
Statements
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) (English)
Roswitha Forstpointner
Michael Unterhalt
Martin Dreyling
Hans-Peter Böck
Roland Repp
Hannes Wandt
Christiane Pott
John F Seymour
Bernd Metzner
Annette Hänel
Tanja Lehmann
Frank Hartmann
Wolfgang Hiddemann
German Low Grade Lymphoma Study Group (GLSG)
31 August 2006